tirzepatide vs liraglutide

updated

tirzepatide (tier S) vs liraglutide (tier S): what each is, half-life and source counts side by side.

the difference

checked

a PubMed search and a ClinicalTrials.gov search on October 24, 2026 found one randomized study with tirzepatide and liraglutide arms, a six-week phase 1 study of eating behavior in 114 adults without diabetes (NCT04311411), and its primary outcome compared tirzepatide with placebo.

tirzepatide is FDA-approved as Mounjaro for type 2 diabetes, including lowering cardiovascular risk in adults at high risk, and as Zepbound for long-term weight reduction and for obstructive sleep apnea in adults with obesity.

liraglutide is FDA-approved as Victoza for type 2 diabetes, including lowering cardiovascular risk in adults with established cardiovascular disease, and as Saxenda for long-term weight reduction.

tirzepatide · tier S

A dual GIP and GLP-1 receptor agonist with distinct Zepbound and Mounjaro labels.

tier rationale

Tirzepatide is in S tier because large randomized trials have shown weight loss, improved blood-sugar control and reduced sleep-apnea severity. Zepbound and Mounjaro have US approvals for these uses.

liraglutide · tier S

A once-daily GLP-1 receptor agonist sold under separate Saxenda and Victoza labels.

tier rationale

S reflects approved uses, the 3,731-person SCALE weight-management trial, and the 9,340-person LEADER cardiovascular-outcomes trial. Saxenda and Victoza use different target exposures and evidence packages.

at a glance

tirzepatideliraglutide
tierSS
categoryweight lossweight loss
sources208
claims evaluatedn/an/a
half-life~5 days~13 hours
dosing datayesyes

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.